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Background
First-line palliative treatment for patients with R/M
SCCHN includes platinum-based chemotherapy. There
are no standard second-line options upon relapse and
median survival is limited. In SCCHN, tumors create a
highly immunosuppressive environment and evade
immune detection by exploiting inhibitory immune
checkpoints such as the programmed cell death ligand-1
(PD-L1)/programmed cell death-1 (PD-1) axis, making
immunotherapy an attractive option to study in this dis-
ease. Durvalumab (MEDI4736) is a selective, high affi-
nity human IgG1 mAb that blocks PD-L1 binding to
PD-1 (IC50 0.1 nM) and CD80 (IC50 0.04 nM) that has
shown promising antitumor activity in the SCCHN
cohort of a Phase I/II study (NCT01693562). Tremeli-
mumab is a selective human IgG2 mAb inhibitor of
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)
that has been combined with durvalumab in a Phase Ib
study in patients with NSCLC (NCT02000947), with
encouraging clinical activity and a manageable safety
profile. While anti-PD-1/PD-L1 monotherapy may be
associated with greater clinical benefit in patients with PD-
L1+ tumors, combination therapy has clinical activity in
both PD-L1+ and PD-L1– patients in several solid tumors,
enhancing the antitumor activity of anti-PD-1/PD-L1
agents in patients with PD-L1– tumors. The PD-L1 and
CTLA-4 pathways are non-redundant and preclinical
data indicate targeting both may induce synergistic antitu-
mor effects. Here we describe the CONDOR study
(NCT02319044), a Phase II study to determine the efficacy
and safety of durvalumab monotherapy, tremelimumab
monotherapy, and their combination in PD-L1– R/M
SCCHN patients who have failed prior platinumtherapy.
Methods
This is a randomized, open-label, multicenter, global,
Phase II study in immunotherapy-naïve patients with PD-
L1– R/M SCCHN who have progressed during or after
treatment with a platinum-containing regimen for R/M
disease. Patients with tumoral PD-L1 expression below a
pre-specified cut-off level of < 25% tumor cells with mem-
brane staining, as determined by an immunohistochemis-
try assay, are deemed PD-L1–. Patients (N=240) will be
randomized 1:1:2 to receive durvalumab (10 mg/kg IV)
monotherapy; tremelimumab (10 mg/kg IV) monotherapy;
or durvalumab (20 mg/kg IV) plus tremelimumab (1 mg/
kg IV) combination therapy for up to 12 months (Figure
1). Stratification factors include human papillomavirus
(HPV) and smoking history. The primary endpoint is
objective response rate (ORR; RECIST v1.1), based on
independent central review. Secondary endpoints will
further assess disease control rate, duration of response,1Vanderbilt University, Nashville, TN, USA
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progression-free survival, and overall survival; safety
(CTCAE v4.03) and tolerability; and health-related quality
of life. Exploratory outcomes include pharmacokinetics,
immunogenicity, and potential biomarkers of response to
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